Project Grant R01CA300706
Award Date
4/7/25
Completion Date
3/31/30
Dollars Obligated
$631K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
The federal Project Grant award R01CA280194 provides funding of $622,329 to Virginia Commonwealth University (VCU) from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) to develop an effective small molecule inhibitor (PDZ1I) that can simultaneously inhibit the dissemination and growth/survival of progressive triple-negative breast cancer (TNBC). The research aims to: 1) Formulate PDZ1I for clinical applications and characterize non-cell-autonomous mechanisms by...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $676,584 Project Grant to the University of Texas MD Anderson Cancer Center to study the genomic and phenotypic evolution of metastatic precursor cells in triple-negative breast cancer (TNBC). The 5-year project, running from April 1, 2025 to March 31, 2030, aims to expand the fundamental understanding of TNBC metastasis by investigating the co-evolution of cancer cell intrinsic alterations and their interactions...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $472,447 to Mayo Clinic to conduct preclinical and clinical characterization of DNA methyltransferase (DNMT) inhibitors in combination with standard chemoimmunotherapy for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: Evaluate the activity and mechanisms of DNMT inhibitors plus chemoimmunotherapy in TNBC patients with high DNMT3A expression,...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research at Cold Spring Harbor Laboratory (CSHL) to optimize anti-NMDAR antibodies for the treatment of triple-negative breast cancer (TNBC). The key products and services to be delivered include: Establishing an orthotopic mouse model of NMDAR-positive TNBC to enable the isolation and characterization of NMDAR-reactive antibodies through single-cell RNA...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $460,977 aims to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to generate antitumor CD8+ T cell responses for the treatment of triple-negative breast cancer (TNBC). The project will focus on leveraging chemotherapy-induced changes in splicing and intron retention to generate cancer-specific, non-mutated neoantigens that can potentially be recognized by...
This Project Grant award, totaling $719,799, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program. The award supports research to investigate the role of the metabolic enzyme PFKFB4 in regulating the tumor microenvironment and immune function in metastatic triple-negative breast cancer (TNBC). The research aims to: Elucidate the bifunctional mechanisms by which PFKFB4 kinase and phosphatase activities regulate metabolic and genetic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $512,582 to the University of Massachusetts Medical School over a 5-year period beginning June 1, 2024. The goal of this research is to develop a novel therapeutic approach for overcoming resistance to radiation therapy in triple negative breast cancer (TNBC). The project will investigate the mechanism by which vascular endothelial growth factor (VEGF) signaling through neuropilin-2...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This federal Project Grant award, valued at $542,721.00 and awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports research to develop a ferritin-degrading proteolysis targeting chimera (DEFER) molecule and a platelet-based delivery system to inhibit the growth of triple-negative breast cancer (TNBC). The key products and services to be...
This federal Project Grant award of $545,983 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Northwestern University to identify molecular regulators of interactions between circulating tumor cells (CTCs) and the host immune system, with a focus on the aggressive triple-negative breast cancer (TNBC) subtype. The key objectives are to: 1) Determine the clinical relevance of the PB2 signaling pathway in TNBC, 2) Elucidate the molecular mechanisms...